Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 96Carcinoma, Non-Small-Cell Lung 85Prostatic Neoplasms 75Multiple Myeloma 74Neoplasms 50Leukemia, Myeloid, Acute 44Lymphoma 43Melanoma 42Neoplasm Metastasis 39Ovarian Neoplasms 37Squamous Cell Carcinoma of Head and Neck 35Lymphoma, Non-Hodgkin 34Lung Neoplasms 34Leukemia, Lymphocytic, Chronic, B-Cell 32Hematologic Neoplasms 29Colorectal Neoplasms 29Triple Negative Breast Neoplasms 27Hodgkin Disease 24Pancreatic Neoplasms 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Myelodysplastic Syndromes 21Fallopian Tube Neoplasms 21Carcinoma, Renal Cell 21Sarcoma 20Lymphoma, Follicular 20Urinary Bladder Neoplasms 18Recurrence 18Lymphoma, Mantle-Cell 18Head and Neck Neoplasms 18Brain Neoplasms 18

Interventions

osimertinib 1Gefitinib 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer × 90 days × Clear all
NCT02296125 2026-04-21

FLAURA

AstraZeneca

Phase 3 Completed
674 enrolled 21 charts 1 FDA
Thoracic

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡